Efficacy of hyaluronic acid injection on osteoarthritis patients

Efficacy of single high-molecular-weight versus triple low-molecular-weight hyaluronic acid intra-articular injection among knee osteoarthritis patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130523013442N24

Enrollment

Registered

2018-07-13

Start date

2017-01-01

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group 1: high-molecular-weight hyaluronic acid ((with trade name "Arthromac", made in France

"Crespine", made in Germany

"Hyalone", made in Italy), knee intra-articular injection, single injection. Intervention 2: Intervention group 2: low-molecular-weight hyaluronic acid (with trade name "Hyalgan", made in Italy), knee

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with knee osteoarthritis according to the American College of Rheumatology aged 40-75 years old persistent symptoms more than 3 months in spite of conservative treatment grade 2 or 3 based on KLS system in plain x-ray film

Exclusion criteria

Exclusion criteria: Systemic illness such as diabetes mellitus, immunodeficiency and vascular collagen diseases prior history of cancer or active malignancy infection or/and active wounds in knee pregnancy or breast-feeding allergy to avian products, feathers and egg proteins gout or pseudo-gout BMI more than 35 recent knee trauma genuvarum or valgum exceeding 20 degrees history of knee intra-articular injection over the past 3 months

Design outcomes

Primary

Measure	Time frame
Knee pain. Timepoint: Before intervention and 8 & 24 weeks after injection. Method of measurement: WOMAC questionnaire.;Knee pain. Timepoint: Before intervention and 8 & 24 weeks after injection. Method of measurement: VAS questionnaire.	—

Secondary

Measure	Time frame
Joint stiffness. Timepoint: Before intervention and 8 & 24 weeks after injection. Method of measurement: WOMAC questionnaire.;Patient function. Timepoint: Before intervention and 8 & 24 weeks after injection. Method of measurement: WOMAC questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Cheraghi

Physical Medicine and Rehabilitation Department, Shahid Beheshti University of Medical Sciences

mohsencheraghi2000@gmail.com+98 21 2236 3244

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026